Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
Angela R. Branche, Nadine G. Rouphael, Cecilia Losada, Lindsey R. Baden, Evan J. Anderson, Anne F. Luetkemeyer, David J. Diemert, Patricia L. Winokur, Rachel M. Presti, Angelica C. Kottkamp, Ann R. Falsey, Sharon E. Frey, Richard Rupp, Martín Bäcker, Richard M. Novak, Emmanuel B. Walter, Lisa A. Jackson, Susan J. Little, Lilly C. Immergluck, Siham M. MahgoubJennifer A. Whitaker, Tara M. Babu, Paul A. Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Antonia Netzl, Derek J. Smith, Kalyani Telu, Jinjian Mu, Mat Makowski, Mamodikoe K. Makhene, Sonja Crandon, David C. Montefiori, Paul C. Roberts, John H. Beigel
Dive into the research topics of 'Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial'. Together they form a unique fingerprint.